Clinical trial · no report yet · Phase 2
PAPMET2
Testing Cabozantinib With or Without Atezolizumab in Patients With Advanced Papillary Kidney Cancer, PAPMET2 Trial
- NCT05411081 ↗
- Active, not recruiting
- National Cancer Institute (NCI)
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 33 | |
| YouTube | 20 | |
| Podcasts | 9 | |
| X videos | 1 |
The trial
ClinicalTrials.gov- Official title
- A Phase II Randomized Trial of Cabozantinib (NSC #761968) With or Without Atezolizumab (NSC #783608) in Patients With Advanced Papillary Renal Cell Carcinoma (PAPMET2)
- Phase
- Phase 2
- Status
- Active, not recruiting
- Conditions
- Metastatic Papillary Renal Cell Carcinoma; Stage IV Renal Cell Cancer AJCC v8
- Interventions
- Atezolizumab; Biospecimen Collection; Bone Scan; Cabozantinib S-malate; Computed Tomography; Magnetic Resonance Imaging
- Arms
- Arm I (cabozantinib S-malate) · Active comparator
- Arm II (cabozantinib S-malate, atezolizumab) · Experimental
- Enrollment
- 200 (estimated)
- Primary outcomes
- Progression free survival
- Sponsor
- National Cancer Institute (NCI)
- Start
- Mar 24, 2023
- Primary completion
- Jul 1, 2027 (estimated)
- Results posted
- No
- Registry record
- NCT05411081 · updated Oct 1, 2026